Spots Global Cancer Trial Database for paclitaxel
Every month we try and update this database with for paclitaxel cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Phase II Neoadjuvant Trial of a Continuous Infusion of Paclitaxel Plus Cisplatin Followed by Chest Radiotherapy for Patients With Stage III Non-Small Cell Lung Cancer | NCT00001499 | Carcinoma, Non-... Lung Neoplasms | paclitaxel cisplatin chest radiother... | - | National Institutes of Health Clinical Center (CC) | |
| Paclitaxel and Bortezomib in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors | NCT00667641 | Breast Cancer Colorectal Canc... Head and Neck C... Lung Cancer Melanoma (Skin) Ovarian Cancer Pancreatic Canc... Prostate Cancer Unspecified Adu... | bortezomib paclitaxel | 18 Years - | Rutgers, The State University of New Jersey | |
| Efficacy/Safety of Imprime PGG With Cetuximab & Paclitaxel/Carboplatin Therapy in Pts With Untreated Advanced Non-Small Cell Lung Cancer | NCT00874848 | NSCLC | Imprime PGG Inj... Cetuximab Paclitaxel Carboplatin | 18 Years - 75 Years | HiberCell, Inc. | |
| An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease | NCT03770299 | Non-Small Cell ... Non-Small-Cell ... Circulating Tum... | Nivolumab Vinorelbine Gemcitabine Docetaxel Pemetrexed Cisplatin Carboplatin Paclitaxel Observation | 18 Years - | Bristol-Myers Squibb | |
| A Study of Bevacizumab With Carboplatin and Paclitaxel Chemotherapy for the First-Line Treatment of Patients With Metastatic Melanoma | NCT00434252 | Melanoma | bevacizumab carboplatin paclitaxel placebo | 18 Years - | Genentech, Inc. | |
| Ganetespib in Combination With Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-III Esophageal Cancer | NCT02389751 | Gastroesophagea... Malignant Neopl... Malignant Neopl... Stage IIA Esoph... Stage IIB Esoph... Stage IIIA Esop... Stage IIIB Esop... Stage IIIC Esop... | Carboplatin Ganetespib Paclitaxel Radiation Thera... | 18 Years - | M.D. Anderson Cancer Center | |
| A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors | NCT06139211 | Advanced Solid ... | JS015 Toripalimab Paclitaxel Irinotecan Capecitabine Oxaliplatin Bevacizumab Fluorouracil Leucovorin Gemcitabine Albumin-Bound P... | 18 Years - 75 Years | Shanghai Junshi Bioscience Co., Ltd. | |
| A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | NCT06161025 | Solid Cancer | R-DXd Gemcitabine Paclitaxel Topotecan PLD | 18 Years - | Daiichi Sankyo | |
| Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian or Primary Peritoneal Cancer | NCT00005046 | Ovarian Cancer Primary Periton... | chemotherapy paclitaxel | 21 Years - | GOG Foundation | |
| TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer | NCT01493505 | Fallopian Tube ... Ovarian Cancer Peritoneal Canc... | AMG 386 Paclitaxel AMG 386 Placebo Carboplatin | 18 Years - | Amgen | |
| Reirradiation With Concurrent Paclitaxel for Breast Cancer | NCT02058667 | Breast Cancer | Paclitaxel+Init... | 18 Years - | University of Kentucky | |
| First in Human Study of UCT-01-097 in Participants With Advanced Solid Tumors | NCT04761601 | Advanced Solid ... | UCT-01-097 Gemcitabine Paclitaxel | 18 Years - | 1200 Pharma, LLC | |
| Paclitaxel, Ifosfamide and Cisplatin (TIP) Versus Bleomycin, Etoposide and Cisplatin (BEP) for Patients With Previously Untreated Intermediate- and Poor-risk Germ Cell Tumors | NCT01873326 | Germ Cell Tumor... | Paclitaxel Ifosfamide Cisplatin Mesna Bleomycin Etoposide | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Biomarker Study in Patients With HER2-negative Metastatic Breast Cancer Treated With Bevacizumab and Paclitaxel | NCT01722968 | Breast Cancer | Bevacizumab Paclitaxel | 18 Years - 70 Years | Karolinska University Hospital | |
| S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer | NCT00661193 | Lung Cancer | carboplatin erlotinib hydro... paclitaxel | 18 Years - 120 Years | SWOG Cancer Research Network | |
| Combination Chemotherapy, Amifostine, and Peripheral Stem Cell Transplantation in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer | NCT00003927 | Breast Cancer | filgrastim amifostine trih... cyclophosphamid... doxorubicin hyd... paclitaxel peripheral bloo... | 18 Years - 59 Years | City of Hope Medical Center | |
| Phase II Study Evaluating the Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Chemotherapy as First-line Treatment for Participants With Advanced Triple Negative Breast Cancer | NCT05809895 | Triple Negative... | Ociperlimab Tislelizumab Paclitaxel Nab-paclitaxel Carboplatin Placebo Pembrolizumab Gemcitabine | 18 Years - | Novartis | |
| Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2). | NCT04472429 | Squamous Cell C... | carboplatin paclitaxel retifanlimab | 18 Years - | Incyte Corporation | |
| Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling | NCT01868022 | Neoplasms | GSK3052230 paclitaxel carboplatin docetaxel pemetrexed cisplatin | 18 Years - | GlaxoSmithKline | |
| Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer | NCT01855828 | Her2-Positive B... | Pertuzumab Trastuzumab Paclitaxel 5-fluorouracil Epirubicin Cyclophosphamid... | 18 Years - 65 Years | Yale University | |
| Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB Non-Small Cell Lung Cancer | NCT02621398 | Stage II Non-Sm... Stage IIIA Non-... Stage IIIB Non-... | 3-Dimensional C... Carboplatin Intensity-Modul... Laboratory Biom... Paclitaxel Pembrolizumab | 18 Years - | Rutgers, The State University of New Jersey | |
| Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer | NCT02810457 | Carcinoma, Non-... | FKB238 (bevaciz... Avastin (bevaci... Paclitaxel Carboplatin | 18 Years - | Centus Biotherapeutics Limited | |
| A Safety and Efficacy Study of BCD-022 With Paclitaxel Compared to Herceptin With Paclitaxel in HER2+ Metastatic Breast Cancer Patients | NCT01764022 | Human Epithelia... | Trastuzumab Paclitaxel | 18 Years - 75 Years | Biocad | |
| Effect of Tumor Treating Fields (TTFields, 200 kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer (ENGOT-ov50 / GOG-3029 / INNOVATE-3) | NCT03940196 | Ovarian Cancer | NovoTTF-100L(O) Paclitaxel | 18 Years - | NovoCure Ltd. | |
| A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Untreated, Advanced Non-Small Cell Lung Cancer | NCT01268059 | Non-small Cell ... | Carboplatin Paclitaxel MEDI-575 | 18 Years - 99 Years | MedImmune LLC | |
| Trastuzumab (Herceptin), Paclitaxel, Carboplatin and Gemcitabine in Advanced Urothelial Cancer | NCT00151034 | Urologic Neopla... | Trastuzumab Paclitaxel Carboplatin Gemcitabine | 18 Years - | University of Michigan Rogel Cancer Center | |
| Paclitaxel Plus Capecitabine With Capecitabine Maintenance Treatment in Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction | NCT01015339 | Advanced Gastri... | Paclitaxel capecitabine capecitabine cisplatin | 18 Years - | Peking University | |
| Phase I Trial of Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin Plus Early Postoperative Intraperitoneal Paclitaxel and 5-FU for Peritoneal Carcinomatosis | NCT00001569 | Carcinoma Peritoneal Neop... | Cisplatin Paclitaxel 5-FU | - | National Institutes of Health Clinical Center (CC) | |
| Dose Escalation Study of BIBF 1120 in Patients With Advanced Gynaecological Malignancies | NCT02182245 | Genital Neoplas... | BIBF 1120 Paclitaxel Carboplatin | 18 Years - | Boehringer Ingelheim | |
| Phase II Study Evaluating the Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Chemotherapy as First-line Treatment for Participants With Advanced Triple Negative Breast Cancer | NCT05809895 | Triple Negative... | Ociperlimab Tislelizumab Paclitaxel Nab-paclitaxel Carboplatin Placebo Pembrolizumab Gemcitabine | 18 Years - | Novartis | |
| Carboplatin, Paclitaxel, and Temozolomide for Patients With Metastatic Melanoma | NCT01009515 | Melanoma | Paclitaxel, car... | 18 Years - | New Mexico Cancer Care Alliance | |
| Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients With Advanced NSCLC Progressing After Immunotherapy & Chemotherapy | NCT05781308 | Non Small Cell ... | Paclitaxel Bevacizumab Atezolizumab | 18 Years - | Intergroupe Francophone de Cancerologie Thoracique | |
| A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) | NCT04222972 | RET-fusion Non ... Lung Neoplasm Carcinoma, Non-... Respiratory Tra... Thoracic Neopla... Neoplasms by Si... Neoplasms Lung Diseases Respiratory Tra... Carcinoma, Bron... Bronchial Disea... Head and Neck N... Adenocarcinoma Carcinoma Neoplasms by Hi... Neoplasms, Germ... Neoplasms, Nerv... | Pralsetinib Carboplatin Cisplatin Pemetrexed Pembrolizumab Gemcitabine Paclitaxel Nab-Paclitaxel | 18 Years - | Hoffmann-La Roche | |
| Ascending Multiple-Dose Study of Brivanib Alaninate in Combination With Chemotherapeutic Agents in Subjects With Advanced Cancers | NCT00798252 | Advanced Cancer | Capecitabine Doxorubicin Ixabepilone Docetaxel Paclitaxel Brivanib alanin... | 18 Years - 75 Years | Bristol-Myers Squibb | |
| Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | NCT02272790 | Ovarian, Fallop... | Adavosertib Paclitaxel Carboplatin Gemcitabine PLD | 18 Years - 130 Years | AstraZeneca | |
| Randomized Phase III Trial Comparing Sequential Administration of FE75C Followed by Docetaxel Versus Paclitaxel as Adjuvant Chemotherapy in Axillary Lymph Node (+) Breast Cancer | NCT00431080 | Breast Cancer | Docetaxel Paclitaxel Epirubicin Cyclophosphamid... 5-fluoruracil Granulocyte-col... | 18 Years - 75 Years | Hellenic Oncology Research Group | |
| A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer | NCT02514551 | Gastric Adenoca... Gastroesophagea... | Ramucirumab Paclitaxel | 18 Years - | Eli Lilly and Company | |
| Flavopiridol and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer That Has Not Responded to Previous Paclitaxel | NCT00006245 | Esophageal Canc... | alvocidib paclitaxel | 18 Years - | National Cancer Institute (NCI) | |
| Paclitaxel, Ifosfamide, and Cisplatin in Treating Patients With Metastatic Testicular Cancer | NCT00004077 | Testicular Germ... | cisplatin ifosfamide paclitaxel | 16 Years - 64 Years | National Cancer Institute (NCI) | |
| Adjuvant Stage 2-3A Breast Cancer With Positive Lymph Nodes | NCT00007904 | Breast Cancer | filgrastim cyclophosphamid... doxorubicin hyd... paclitaxel tamoxifen citra... adjuvant therap... radiation thera... | 18 Years - | Case Comprehensive Cancer Center | |
| Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer | NCT00063999 | Recurrent Uteri... Stage IIIA Uter... Stage IIIB Uter... Stage IIIC Uter... Stage IVA Uteri... Stage IVB Uteri... | Carboplatin Cisplatin Doxorubicin Hyd... Filgrastim Laboratory Biom... Paclitaxel Pegfilgrastim Quality-of-Life... | 18 Years - | GOG Foundation | |
| Adjuvant Therapeutic Cancer Vaccine (AST-201, pUMVC3-hIGFBP-2) in Patients With Advanced Ovarian Cancer | NCT05794659 | Advanced Ovaria... | AST-201 Paclitaxel Carboplatin Placebo rhuGM-CSF(Granu... | 18 Years - | Aston Sci. Inc. | |
| Chemotherapy With or Without Surgical Resection in Locally Advanced Esophageal Cancer | NCT00193141 | Esophagus Cance... | Paclitaxel Carboplatin 5-Fluorouracil | 18 Years - | SCRI Development Innovations, LLC | |
| Paclitaxel With or Without Trastuzumab in Treating Patients With or Without HER-2/Neu Breast Cancer That is Inoperable, Recurrent, or Metastatic | NCT00003440 | HER2-negative B... HER2-positive B... Recurrent Breas... Stage IIIC Brea... Stage IV Breast... | paclitaxel trastuzumab quality-of-life... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Pharmacogenomics of Paclitaxel in Ovarian Cancer | NCT00415207 | Ovarian Neoplas... Fallopian Tube ... | 18 Years - | University of Southern Denmark | ||
| Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) - China Extension Study | NCT04865289 | Endometrial Neo... | Lenvatinib Pembrolizumab Paclitaxel Carboplatin | 18 Years - | Merck Sharp & Dohme LLC | |
| Dose Escalating Study With BAY43-9006 With Carboplatin, Paclitaxel and Bevacizumab in Untreated Stage IIIb Non-small Cell Lung Cancer (NSCLC) | NCT01069328 | Carcinoma, Non-... Lung Cancer | Nexavar (Sorafe... Nexavar (Sorafe... Bevacizumab Bevacizumab Bevacizumab Bevacizumab Paclitaxel Carboplatin | 18 Years - | Bayer | |
| Bcl-2 Antisense Oligodeoxynucleotide G3139 and Paclitaxel in Treating Patients With Recurrent Small Cell Lung Cancer | NCT00005032 | Lung Cancer | oblimersen sodi... paclitaxel | 18 Years - | University of Chicago | |
| Study of Weekly Paclitaxel and Cisplatin in FIGO IB2 and IIA2 Cervical Cancer Followed by Radical Hysterectomy | NCT02432365 | Cervical Cancer | paclitaxel cisplatin Radical hystere... | 35 Years - 70 Years | Chang Gung Memorial Hospital | |
| Clinical Study of Decitabine and Paclitaxel Combination Therapy | NCT03282825 | Advanced Breast... | Decitabine Paclitaxel | 19 Years - | Dong Wha Pharmaceutical Co. Ltd. | |
| Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer | NCT03367871 | Cervical Cancer | Pembrolizumab Paclitaxel Cisplatin Carboplatin Bevacizumab | 18 Years - | University of Miami | |
| Paclitaxel and Cisplatin as First-Line Treatment for Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer | NCT00964626 | Ovarian Cancer | cisplatin paclitaxel | 18 Years - 72 Years | National Cancer Institute (NCI) | |
| Trial Comparing Niraparib-bevacizumab-Dostarlimab and Niraparib-bevacizumab to Standard of Care in Recurrent Ovarian Cancer | NCT03806049 | Ovarian Cancer | Niraparib Bevacizumab TSR042 Carboplatin Paclitaxel | 18 Years - 100 Years | Nordic Society of Gynaecological Oncology - Clinical Trials Unit | |
| Molecular Triaging of Newly Diagnosed Breast Cancer | NCT01159236 | Breast Cancer | Paclitaxel Fluorouracil Doxorubicin Epirubicin Cyclophosphamid... Bevacizumab | 18 Years - | M.D. Anderson Cancer Center | |
| Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Positive Breast Cancer | NCT00093795 | Breast Cancer | Cyclophosphamid... Docetaxel Gemcitabine Paclitaxel Doxorubicin | 18 Years - | NSABP Foundation Inc | |
| Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO) | NCT04776447 | Lung Diseases Carcinoma, Non-... Stage IIIA Non-... Stage IIIB Non-... Respiratory Tra... Carcinoma Bronc... Thoracic Neopla... | Carboplatin Placlitaxel Atezolizumab | 18 Years - 75 Years | Fundación GECP | |
| Treatment With Pazopanib for Neoadjuvant Breast Cancer | NCT00849472 | Neoplasms, Brea... | doxorubicin + c... paclitaxel + pa... surgery pazopanib monot... | 18 Years - | GlaxoSmithKline | |
| Itraconazole in Advanced Ovarian Cancer | NCT05591560 | Ovarian Carcino... | Itraconazole ca... Placebo | 18 Years - 65 Years | Tanta University | |
| Phase I/II NabPaclitaxel, Paclitaxel&Carboplatin w RTX Followed by Consolidation in Patients w Favorable Prognosis Inoperable Stage IIIA/B NSCLC | NCT01757288 | STAGE IIIA/B NS... | NAB-PACLITAXEL PACLITAXEL NAB-PACLITAXEL | 18 Years - 99 Years | University of Texas Southwestern Medical Center | |
| Effect of Pembrolizumab With or Without Carboplatin and Paclitaxel on Immune Response in Patients With Recurrent or Stage IIIB-IV Non-small Cell Lung Cancer | NCT02581943 | Recurrent Non-S... Stage IIIB Non-... Stage IV Non-Sm... | Carboplatin Laboratory Biom... Paclitaxel Pembrolizumab Quality-of-Life... | 18 Years - | Wake Forest University Health Sciences | |
| Carboplatin-Paclitaxel-Bevacizumab vs Carbo-Pacli-Beva-Rucaparib vs Carbo-Pacli-Ruca, Selected According to HRD Status, in Patients With Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer, Preceded by a Phase I Dose Escalation Study on Ruca-Beva Combination | NCT03462212 | Advanced (Stage... | Carboplatin Paclitaxel Bevacizumab Rucaparib | 18 Years - | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | |
| A Multi-Institutional Phase II Study of Cyclophosphamide, Paclitaxel, Cisplatin With G-CSF for Patients With Newly Diagnosed Advanced Stage Ovarian Cancer | NCT00001426 | Ovarian Neoplas... | Cyclophosphamid... Paclitaxel Cisplatin G-CSF | - | National Institutes of Health Clinical Center (CC) | |
| Optimizing and Personalising Azacitidine Combination Therapy for Treating Solid Tumours QPOP and CURATE.AI | NCT05381038 | Solid Tumor Gastrointestina... Breast Cancer | QPOP CURATE.AI Azacitidine + d... Azacitidine + p... Azacitidine + i... | 21 Years - 99 Years | National University Hospital, Singapore | |
| Oxaliplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Cervical Cancer | NCT00057863 | Cervical Adenoc... Cervical Adenos... Cervical Squamo... Recurrent Cervi... Stage IVA Cervi... Stage IVB Cervi... | Paclitaxel Oxaliplatin | 18 Years - | National Cancer Institute (NCI) | |
| A Phase 1-2 XIAP Antisense AEG35156 With Carboplatin and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer | NCT00558922 | Carcinoma, Non-... | AEG35156 | 18 Years - | Aegera Therapeutics | |
| Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery | NCT00110019 | Mucosal Melanom... Recurrent Melan... Stage IIIA Skin... Stage IIIB Skin... Stage IIIC Skin... Stage IV Skin M... | Carboplatin Laboratory Biom... Paclitaxel Pharmacological... Placebo Sorafenib Tosyl... | 18 Years - | National Cancer Institute (NCI) | |
| Study of Safety & Efficacy of the Combination of LJM716 & BYL719 in Patients With Previously Treated Esophageal Squamous Cell Carcinoma (ESCC) | NCT01822613 | Esophageal Squa... | LJM716 BYL719 Paclitaxel Docetaxel Irinotecan | 18 Years - | Novartis | |
| Carboplatin and Paclitaxel With or Without Vorinostat in Treating Patients With Advanced Non-Small Cell Lung Cancer | NCT01413750 | Stage IIIA Non-... Stage IIIB Non-... Stage IV Non-Sm... | Paclitaxel Carboplatin Vorinostat Placebo Laboratory Biom... | 18 Years - | National Cancer Institute (NCI) | |
| A Study of Avastin (Bevacizumab) in Combination With Taxane-based Chemotherapy as First Line Treatment in Patients With HER-2 Negative Breast Cancer | NCT00846027 | Breast Cancer | Bevacizumab Paclitaxel Gemcitabine | 18 Years - | Hoffmann-La Roche | |
| A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies | NCT00781612 | Neoplasm Metast... | Docetaxel Paclitaxel Pertuzumab Trastuzumab Trastuzumab Emt... Atezolizumab | 18 Years - | Genentech, Inc. | |
| Paclitaxel, Carboplatin Plus Bevacizumab in Pretreated, Advanced or Metastatic Non Small Cell Lung Cancer | NCT00753909 | Non Small Cell ... | Carboplatin Bevacizumab Paclitaxel | 18 Years - | Hellenic Oncology Research Group | |
| Combination Chemotherapy and Autologous Peripheral Stem Cell Transplant in Treating Patients With Stage III, Stage IV, or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | NCT00550784 | Fallopian Tube ... Ovarian Cancer Peritoneal Cavi... | filgrastim cisplatin cyclophosphamid... melphalan paclitaxel topotecan hydro... TdT-mediated dU... gene expression... immunohistochem... pharmacological... peripheral bloo... | - 60 Years | City of Hope Medical Center | |
| A Phase 1-2 XIAP Antisense AEG35156 With Carboplatin and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer | NCT00558922 | Carcinoma, Non-... | AEG35156 | 18 Years - | Aegera Therapeutics | |
| Pulsed Dose Chemotherapy Plus Pembrolizumab in Recurrent/Metastatic HNSCC | NCT06052839 | Recurrent/Metas... | Pembrolizumab Carboplatin Paclitaxel | 18 Years - | University of Pittsburgh | |
| Trial of NanoPac Focal Therapy for Prostate Cancer | NCT04221828 | Prostate Cancer Prostate Adenoc... Prostate Cancer... Prostatic Neopl... Urogenital Neop... Genital Neoplas... Localized Cance... | NanoPac (steril... | 18 Years - | NanOlogy, LLC | |
| Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary Cancer | NCT05185947 | Gynecologic Can... Gynecologic Neo... Peritoneal Carc... Peritoneal Neop... Ovarian Cancer Ovarian Neoplas... Colorectal Canc... Colorectal Neop... Appendiceal Can... Appendiceal Neo... | Paclitaxel Nilotinib | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Intraperitoneal Paclitaxel and Carboplatin in the Treatment of Women With Carcinoma of Mullerian Origin | NCT00181701 | Ovarian Carcino... | Paclitaxel Carboplatin | 18 Years - | Massachusetts General Hospital | |
| Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer | NCT05415709 | Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Ovarian Endomet... Ovarian Mucinou... Ovarian Serous ... Primary Periton... Primary Periton... Stage III Fallo... Stage III Ovari... Stage III Prima... Stage IIIA Fall... Stage IIIA Ovar... Stage IIIA Prim... Stage IIIA1 Fal... Stage IIIA1 Ova... Stage IIIA2 Fal... Stage IIIA2 Ova... Stage IIIB Fall... Stage IIIB Ovar... Stage IIIB Prim... Stage IIIC Fall... Stage IIIC Ovar... Stage IIIC Prim... Stage IV Fallop... Stage IV Ovaria... Stage IV Primar... Stage IVA Fallo... Stage IVA Ovari... Stage IVA Prima... Stage IVB Fallo... Stage IVB Ovari... Stage IVB Prima... | Carboplatin Cisplatin Cytoreductive S... Hyperthermic In... Paclitaxel Quality-of-Life... Questionnaire A... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer. | NCT01924533 | Gastric Cancer | Olaparib Paclitaxel Placebo | 18 Years - 99 Years | AstraZeneca | |
| A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer | NCT03742102 | Triple Negative... | Durvalumab Capivasertib Oleclumab Paclitaxel Trastuzumab der... Datopotamab der... | 18 Years - 130 Years | AstraZeneca |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
